<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35507054</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1747-4094</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>11</Day>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of hematology</Title>
          <ISOAbbreviation>Expert Rev Hematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?</ArticleTitle>
        <Pagination>
          <StartPage>1</StartPage>
          <EndPage>7</EndPage>
          <MedlinePgn>1-7</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/17474086.2022.2074393</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The development of BTK inhibitors has revolutionized the management of CLL. Currently, there are 3 BTK inhibitors available to treat CLL: ibrutinib, acalabrutinib, and zanubrutinib (the latter not yet approved for this disease but included in the NCCN guidelines). In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy.</AbstractText>
          <AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">This review utilizes data from published prospective trials, specifically RESONATE, RESONATE-2, ELEVATE-TN, ASCEND, ELEVATE-RR, and the ongoing FLAIR, SEQUOIA, and ALPINE trials.</AbstractText>
          <AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">The choice of BTK inhibitor is guided by the setting (frontline vs relapsed) in conjunction with patient disease characteristics and comorbidities. In this review, we will elucidate our approach to the selection of BTK inhibitor and provide insight into the future of BTK directed therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Desikan</LastName>
            <ForeName>Sai Prasad</ForeName>
            <Initials>SP</Initials>
            <Identifier Source="ORCID">0000-0003-1157-6489</Identifier>
            <AffiliationInfo>
              <Affiliation>Departments of Leukemia, The University of Texas Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venugopal</LastName>
            <ForeName>Sangeetha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Leukemia, The University of Texas Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ferrajoli</LastName>
            <ForeName>Alessandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Leukemia, The University of Texas Houston, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Rev Hematol</MedlineTA>
        <NlmUniqueID>101485942</NlmUniqueID>
        <ISSNLinking>1747-4094</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CLL</Keyword>
        <Keyword MajorTopicYN="N">acalabrutinib</Keyword>
        <Keyword MajorTopicYN="N">atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="N">bleeding</Keyword>
        <Keyword MajorTopicYN="N">hypertension</Keyword>
        <Keyword MajorTopicYN="N">ibrutinib</Keyword>
        <Keyword MajorTopicYN="N">zanubrutinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>11</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35507054</ArticleId>
        <ArticleId IdType="doi">10.1080/17474086.2022.2074393</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
